文献速递肺栓塞与肺血管病

澳大利亚和新西兰慢性血栓栓塞性肺动脉高压:PHSANZ登记分析

Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry.
PubMed 文献 · Respirology · 2021-10-05

基于PHSANZ登记2004年1月至2020年3月确诊的386例CTEPH患者,37.8%接受PEA,PEA组较非PEA组年轻且基线6MWD更高,两组基线肺血流动力学相似。PEA组1、3、5年生存率分别为93%、87%、84%,非PEA组为86%、73%、62%(p<0.001)。基线6MWD是手术和药物治疗患者生存的独立预测因素。

要点

  • PEA组1、3、5年生存率分别为93%、87%、84%,非PEA组为86%、73%、62%。
  • 仅37.8%的CTEPH患者接受PEA,显著低于海外报道。
  • 基线6MWD是手术和药物治疗患者生存的独立预测因素。

核心结论

  • 澳大利亚和新西兰CTEPH长期生存与其他当代CTEPH登记相当,但PEA仅施行于少数患者(37.8%),显著低于海外报道。
  • 提高对PEA的认识和改善患者获得经验丰富CTEPH中心的机会是重要优先事项。

研究设计与样本

  • 数据提取自澳大利亚和新西兰肺动脉高压学会(PHSANZ)登记,纳入2004年1月至2020年3月确诊的CTEPH患者。
  • 共纳入386例患者,146例(37.8%)接受PEA,240例(62.2%)为非PEA组。

主要发现

  • PEA组患者较非PEA组年轻(55 ± 16 vs. 62 ± 16岁,p < 0.001)。
  • PEA组基线6分钟步行距离(6MWD)较高(405 ± 122 vs. 323 ± 146 m,p = 0.021)。
  • 两组基线肺血流动力学相似。
  • PEA组54%使用肺动脉高压特异性治疗,非PEA组88%。
  • PEA组1、3、5年生存率分别为93%、87%、84%,非PEA组为86%、73%、62%(p < 0.001)。

关键数值与推荐

  • CTEPH在急性肺栓塞后发生于2%-4%的患者。
  • PEA组1、3、5年生存率分别为93%、87%、84%,非PEA组为86%、73%、62%(p < 0.001)。
  • 多因素生存分析显示基线6MWD是手术和药物治疗患者生存的独立预测因素。

临床怎么用

  • CTEPH患者应评估PEA可操作性,并转诊至经验丰富的CTEPH中心。
  • 基线6MWD可用于风险分层和生存预测。

局限性

  • 为登记数据分析,非随机对照研究。
  • PEA组与非PEA组基线特征存在差异(年龄、6MWD)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition occurring in 2%-4% of patients after acute pulmonary embolism. Pulmonary endarterectomy (PEA) is a potential cure for technically operable disease. The epidemiology and long-term outcomes of CTEPH have not been previously described in Australia and New Zealand. METHODS: Data were extracted from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry for patients diagnosed with CTEPH between January 2004 and March 2020. Baseline characteristics, treatment strategies, outcome data and long-term survival are reported. RESULTS: A total of 386 patients were included with 146 (37.8%) undergoing PEA and 240 (62.2%) in the non-PEA group. PEA patients were younger (55 ± 16 vs. 62 ± 16 years, p < 0.001) with higher baseline 6-min walk distance (6MWD; 405 ± 122 vs. 323 ± 146 m, p = 0.021), whilst both groups had similar baseline pulmonary haemodynamics. Pulmonary hypertension-specific therapy was used in 54% of patients post-PEA and 88% in the non-PEA group. The 1-, 3- and 5-year survival rates were 93%, 87% and 84% for the PEA group compared to 86%, 73% and 62%, respectively, for the non-PEA group (p < 0.001). Multivariate survival analysis showed baseline 6MWD was an independent predictor of survival in both operated and medically managed patients. CONCLUSION: In this first multicentre report of CTEPH in Australia and New Zealand, long-term survival is comparable to that in other contemporary CTEPH registries. However, PEA was only performed in a minority of CTEPH patients (37.8%) and significantly less than overseas reports. Greater awareness of PEA and improved patient access to experienced CTEPH centres are important priorities.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Kearney K, Gold J, Corrigan C, et al. Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry. Respirology. 2021. PMID: 34608706. doi:10.1111/resp.14162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。